Researchers have developed an algorithm that can predict which cancer patients are more likely to benefit from immunotherapy.
Truncated proteins (nonsense mutations) can give rise to hereditary diseases and different types of cancer. To keep the number of truncated proteins to a minimum, human cells recognise and remove RNAs with nonsense mutations through a quality control process known as nonsense-mediated mRNA decay (NMD).
To better understand the effect of NMD on human disease, researchers built NMDetective, a tool describing every possible nonsense mutation that can occur in the human genome. Developed by large-scale statistical analyses based on machine learning, the algorithm identifies which mutations in the genome are susceptible to NMD.
As described in Nature Genetics, scientists used NMDetective to analyse thousands of genetic variants that give rise to hereditary diseases in humans. “We were surprised to observe that, in many cases, NMD activity was predicted to lead to a greater severity of the disease,” says Fran Supek, ICREA researcher, head of the Genome Data Science laboratory at IRB Barcelona and leader of the team that built the tool.
The results of the study suggests that pharmacological NMD inhibition could slow the progression of many different genetic diseases. To distinguish which patients would benefit from this therapy, it is necessary to apply a precision medicine approach to determine the mutation responsible for the disease and the effect of NMD on this mutation, and this is precisely where NMDetective comes into play.
Researchers also studied the role of NMD in cancer and the interaction between the tumour and the immune system and found that NMD hides mutations that would otherwise trigger the immune system. Therefore, NMDetective can be used to analyse the mutations present in the tumour, in order to better distinguish between cancer patients that respond to immunotherapy from those who do not respond to immunotherapy.
“Tumours are riddled with genetic mutations that should make all sorts of weird proteins. The immune system should pick these up, identifying the cells gone wrong and destroying them,” says Ben Lehner, a researcher at the Centre for Genomic Regulation who also took part in the study. “But many of these weird proteins never actually get made because of NMD.”
“This algorithm can distinguish which mutations will and won’t trigger this error-checking system. What’s exciting is that drugs that block NMD already exist, which could be used in conjunction with other treatments to help the immune system better recognise tumour cells,” explains Lehner.
“Here we see an example where publicly available cancer genomics data can be ‘reused’ through machine learning approaches to better understand biological processes such as NMD,” says lead author Rik Lindeboom, a researcher at Radboud University in the Netherlands. “What makes this study especially exciting, is that we could directly translate this fundamental research into insights that are relevant for clinicians and patients.”
